clinical trial · NCT05118919
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
BioGaia Pharma AB·phase2·completed·n = 35
Ulcerative ColitisBGP-014Placebo
brief summary
The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.
started
Feb 9, 2022
primary completion
Dec 31, 2024
completion
Dec 31, 2024
last updated
Jun 26, 2025
official title
A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol